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Abstract 
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphoinositide 3-kinase 
(PI3K)-δ and -γ being developed for treatment of hematologic malignancies. PI3K-δ,γ signaling 
can promote B cell proliferation and survival in clonal B cell malignancies, such as chronic 
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In a Phase 1 study, duvelisib 
showed clinically meaningful activity and acceptable safety in CLL/SLL patients. We report here 
the results of DUO™, a global Phase 3 randomized study of duvelisib versus ofatumumab 
monotherapy for patients with relapsed or refractory (RR) CLL/SLL. Patients were randomized 
1:1 to oral duvelisib 25 mg twice daily (BID) (n = 160) or ofatumumab intravenous (IV) 
(n = 159). The study met the primary study endpoint by significantly improving progression-free 
survival (PFS) per Independent Review Committee (IRC) assessment compared to ofatumumab 
for all patients (median 13.3 months versus 9.9 months; hazard ratio [HR] = 0.52; p < 0.0001), 
including those with high-risk chromosome 17p13.1 deletions [del(17p)] and/or TP53 mutations 
(HR = 0.40; p = 0.0002). The overall response rate (ORR) was significantly higher with 
duvelisib (74% versus 45%; p < 0.0001) regardless of del(17p) status. The most common 
adverse events (AEs) were diarrhea, neutropenia, pyrexia, nausea, anemia, and cough on the 
duvelisib arm, and neutropenia and infusion reactions on the ofatumumab arm. The DUO trial 
data support duvelisib as a potentially effective treatment option for patients with RR CLL/SLL. 
This trial is registered at ClinicalTrials.gov as NCT02004522. 
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Key Points 
• Duvelisib significantly improved progression-free survival and overall response rates 
compared to ofatumumab in RR CLL/SLL patients.  
• Duvelisib’s efficacy and manageable safety profile support its consideration as a 
novel, oral monotherapy for RR CLL/SLL patients. 
 
Introduction  
CLL is the most common adult lymphoproliferative disorder in Western countries, with more 
than 20,000 estimated new cases in the United States in 2017 and over 4,600 deaths.1 The timing 
and selection of therapy is largely informed by multiple clinical and biologic factors, specifically 
disease stage, presence of poor prognostic molecular features (eg, del(17p), TP53 mutations) and 
the general status of individual patients, many of whom are elderly with comorbid conditions 
precluding aggressive chemoimmunotherapy.2,3 Chemotherapy, specifically alkylating agents 
and purine analogs, and monoclonal CD20 antibody therapy have long represented the traditional 
backbone of frontline therapy.4 The comparator agent for the DUO trial, ofatumumab, is a 
humanized anti-CD20 antibody with single-agent efficacy against refractory CLL and a Food 
and Drug Administration (FDA)-approved treatment option.5,6 Recently approved therapies 
targeting key pathways of CLL cell proliferation and survival, particularly Bruton’s tyrosine 
kinase (BTK), PI3K-δ, and BCL2, have greatly improved outcomes for CLL patients and have 
been integrated into the CLL treatment landscape.7 However, except for allogeneic stem cell 
transplantation, there is general consensus that current therapies for CLL/SLL are not curative, 
and most patients will ultimately succumb to their disease.8,9 Given the inevitable development 
of resistance or intolerance to available therapies, there remains an urgent need to develop novel 
effective and tolerable CLL/SLL treatment options. 
 
Duvelisib is an oral dual PI3K-δ,γ inhibitor that targets key signaling pathways that promote the 
growth and survival of hematologic malignancies. PI3K-δ inhibition blocks the survival and 
proliferation of malignant B cells,10-12 while PI3K-γ inhibition disrupts the recruitment and 
differentiation of T cells and macrophages within the tumor microenvironment that support 
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malignant B cell maintenance.13-16 Dual PI3K-δ,γ inhibition has shown greater activity in 
preclinical models of CLL than blocking either isoform alone.17-21 Accordingly, duvelisib’s 
unique therapeutic potential offers a novel approach to treat patients with CLL/SLL.  
The efficacy and safety profile of duvelisib monotherapy for the treatment of hematologic 
malignancies was demonstrated in a Phase 1 trial.22,23 Clinically meaningful activity was 
observed in a cohort of RR CLL/SLL patients with a 56% ORR and a median PFS of 15.7 
months.22,24 Reductions in serine/threonine kinase AKT phosphorylation (p-AKT) and 
proliferating (Ki67+) CLL cells were seen in CLL patient samples following duvelisib 
administration, demonstrating pharmacodynamic evidence of PI3K inhibition. Based on the 
combined efficacy, safety, pharmacokinetics, and pharmacodynamic data from this Phase 1 
study, duvelisib 25 mg BID was selected as a clinically active dose for a Phase 3 investigation in 
CLL/SLL.22 
Building on these encouraging Phase 1 results, the global Phase 3 randomized DUO study was 
initiated in 2014 to fully characterize the efficacy and safety of duvelisib monotherapy in patients 
with RR CLL/SLL when compared to an approved standard of care, ofatumumab monotherapy. 
Herein are reported the final analysis results for this trial.  
 
Methods  
Study Design and Treatment 
DUO is a global, multicenter, randomized, open-label, Phase 3 trial comparing the efficacy and 
safety of duvelisib monotherapy with ofatumumab monotherapy for RR CLL/SLL. Between 
January 21, 2014 and December 9, 2015, 319 patients with RR CLL/SLL were randomized 1:1 
to study treatment with duvelisib (n=160) or ofatumumab (n=159) at 62 clinical study sites in 
11 countries. Patients were required to have active CLL/SLL disease necessitating treatment, per 
the International Workshop on CLL (IWCLL)25 criteria or Revised International Working Group 
(IWG)26 criteria that had progressed during or relapsed after at least one previous CLL/SLL 
therapy. Radiologically measurable disease, defined as at least one lymph node or tumor mass 
measuring > 1.5 cm by computed tomography (CT) scan, was required. Other standard eligibility 
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requirements included adequate renal and hepatic function, hemoglobin ≥ 8.0 g/dL, and platelet 
count ≥ 10,000 µL with or without transfusion support. There was no eligibility requirement with 
regards to neutrophil count. Key exclusion criteria included prior treatment with BTK or PI3K-δ  
inhibitors; refractoriness to prior ofatumumab therapy; or a history of Richter’s transformation, 
prolymphocytic leukemia, or allogenic stem cell transplant. Pneumocystis jirovecii prophylaxis 
concomitant with study drug treatment was required for all patients on both treatment arms. Per 
protocol, antiviral prophylaxis was recommended to be implemented at the discretion of the 
treating Investigator.  
Patient stratification at randomization included the presence or absence of del(17p), Grade 4 
cytopenia, and refractoriness/early relapse to purine analog based therapy (defined as progression 
< 12 months after fludarabine/pentostatin). Patients randomized to the duvelisib arm 
self-administered 25 mg capsules BID continuously in 28-day cycles except for the first cycle 
(21 days) to align with administration of ofatumumab infusions. Patients were allowed to take 
duvelisib for up to 18 cycles, until disease progression, or until unacceptable toxicity. Additional 
treatment with duvelisib beyond 18 cycles was allowed based on the judgement of the 
Investigator. Guidance for AE management was provided in the protocol and included dose 
modifications (interruptions and reductions) for treatment-related Grade 2 or higher pneumonitis 
or pneumonia, Grade 3 or higher non-hematologic AEs, febrile neutropenia, and 
thrombocytopenia with hemorrhage.  Corticosteroids were recommended for colitis or persistent 
or recurrent severe diarrhea and in combination with antibiotic therapy in patients presenting 
with pulmonary symptoms or radiographic changes suspicious for pneumonitis. 
Ofatumumab arm dosing was based on the dose and schedule outlined in the approved product 
labeling for monotherapy in relapsed CLL at the time the study was initiated and could not 
exceed the 12 doses (within 7 cycles) as described in the prescribing information.27 
Study visits for duvelisib arm patients occurred on Cycle 1 Day 1 and 8, Cycle 2 Day 1 and 15, 
and Day 1 of every other cycle thereafter. Study visits for ofatumumab arm patients were similar 
except for additional visits on Cycle 1 Day 15, and Cycle 2 Day 8 and 22, for study drug 
infusions. Patients on either treatment arm that experienced radiographically confirmed 
progressive disease (PD) had the option to crossover to a separate extension study to receive the 
opposite therapy.  
For personal use only.on December 6, 2018. by guest  www.bloodjournal.orgFrom 
Flinn et al   Duvelisib, a dual PI3K-δ,γ inhibitor in CLL 
6 
Study Endpoints and Assessments 
The primary endpoint was PFS, defined as time from randomization to first documentation of PD 
as determined by an IRC or death due to any cause. Key secondary endpoints included (1) ORR, 
with overall response (per IRC determination) defined as the best response of complete 
response/remission (CR), CR with incomplete marrow recovery (CRi), partial 
response/remission (PR), or PR with lymphocytosis (PRwL), according to IWCLL25,26 or IWG 
Response Criteria,28 with modification for treatment-related lymphocytosis and (2) overall 
survival (OS). Per protocol, a response of PRwL was limited to patients with lymphadenopathy 
as the only abnormal baseline Group A criterion (eg, no organomegaly and normal blood 
lymphocyte count < 4,000/µL) who achieved a PR ( ≥ 50% reduction in lymphadenopathy) but 
had post-baseline isolated progressive lymphocytosis. Response assessments for both arms 
included complete blood count with differential, CT scan, disease-associated symptom review, 
and bone marrow biopsy (for CR confirmation only) that were performed after every 2 cycles 
until Cycle 7, every 4 cycles until Cycle 19, and then every 6 cycles until disease progression, 
start of new anticancer therapy, or subject withdrawal.  
Efficacy Analysis and Statistics 
PFS was compared between the duvelisib and ofatumumab treatment arms using a stratified 
log-rank test (one-sided) with the overall one-sided significance level controlled at 0.025. The 
HR for duvelisib/ofatumumab and the corresponding 2-sided 95% confidence interval (CI) was 
estimated using a stratified Cox proportional hazards model, and PFS for both arms were plotted 
using the Kaplan-Meier method. The ORR was analyzed using the Cochran-Mantel-Haenszel 
(CMH) test to compare treatments. OS (time from randomization to death) was compared 
between treatment arms using a stratified one-sided log-rank test, and the HR along with the 95% 
CI was estimated using a stratified Cox model. Kaplan-Meier plots for OS were generated for 
each treatment group. The lymph node response rates (≥ 50% reduction in target lymph nodes 
from baseline) between treatment arms was analyzed using the one-sided CMH test.  
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Safety Methods  
AEs and hematology and blood chemistry laboratory values were assessed at each study visit or 
as clinically warranted and coded using MedDRA Version 16.1. The severity of AEs and 
applicable laboratory values was graded according to the NCI-CTCAE Version 4.03. 
Data Sharing Statement 
For original data, please contact nmirza@verastem.com 
 
Results 
Patient Baseline Characteristics and Disposition 
The baseline characteristics and stratification of study patients were well balanced between the 
two treatment arms (Table 1). Patients were predominantly male (60%) with a median age in 
both arms of 69 years. Most patients had a baseline Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) of 0 or 1, with a similar percentage of patients with an ECOG 
PS of 2 (duvelisib 7%; ofatumumab 10%). The median time from initial diagnosis was 7.5 years 
for duvelisib and 6.7 years for ofatumumab, and 56% of patients in both arms were ≥ Rai 
stage III at the start of therapy. Nearly half of duvelisib and ofatumumab-treated patients had 
bulky disease (46% and 45%, respectively), and both arms had similar median baseline 
lymphocyte counts (38 x 109/L and 35 x 109/L). Central laboratory determination of molecular 
features identified del(17p) and/or TP53 mutation in approximately one third of patients 
(duvelisib 31%; ofatumumab 33%) and unmutated IGHV status in 69% and 73% of duvelisib 
and ofatumumab patients, respectively.   
On both study arms, the median number of prior therapies was 2, with approximately one third 
having received ≥ 3 prior lines of therapy (Table S1). Most patients had previously received an 
alkylating agent (93% duvelisib; 95% ofatumumab), a monoclonal antibody (78% duvelisib; 
83% ofatumumab), and purine analog (60% duvelisib; 71% ofatumumab).  
Of the patients randomized into each arm, 158 and 155 patients initiated treatment with duvelisib 
and ofatumumab respectively (Table 2; Figure S1). As of the 19 May 2017 data cutoff date, 
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124 duvelisib-treated patients had discontinued treatment, with the most common reasons being 
AEs (35%), disease progression (22%), subject withdrawal (8%), and death (8%). All 
ofatumumab-treated patients had discontinued treatment; most (67%) completed treatment as per 
protocol, while others discontinued due to disease progression (20%), subject withdrawal (5%), 
and AEs (4%). At the time of disease progression, 8 (5%) duvelisib patients opted to crossover to 
ofatumumab therapy and 89 (57%) ofatumumab-treated patients opted to crossover to duvelisib 
therapy in a separate extension study. Efficacy and safety data for that study will be reported 
separately.  
Efficacy 
The primary efficacy endpoint for this study was PFS as determined by IRC, with ORR and OS 
as key secondary endpoints. With a median overall follow up of 22.4 months for the duvelisib 
and ofatumumab arms, median PFS by blinded IRC review was significantly longer for the 
duvelisib arm compared to the ofatumumab arm (13.3 months vs. 9.9 months, HR = 0.52, 
p<0.0001) (Figure 1A). The estimated probability of being progression-free at 6 months and 
12 months was 78% and 60%, respectively, in the duvelisib arm, and 72% and 39% in the 
ofatumumab arm. Improvement in PFS with duvelisib compared with ofatumumab was also 
observed per Investigator assessment (17.6 months vs. 9.7 months, HR = 0.40; p < 0.0001, 
Figure 1B). PFS was also extended with duvelisib in multiple predefined CLL/SLL subgroups 
examined, including patients with high-risk cytogenetic markers (Figure 2A). In the subset of 
patients with del(17p)/TP53 mutations, median PFS by IRC assessment was 12.7 months with 
duvelisib versus 9.0 months for ofatumumab (HR = 0.40; p = 0.0002), with an estimated 
probability of being progression-free at 6 months and 12 months of 73% and 55% with duvelisib, 
and 63% and 30% with ofatumumab (Figure 2B). By Investigator assessment, median PFS in 
patients with del(17p)/TP53 mutations was 13.8 months with duvelisib and 9.5 months with 
ofatumumab (HR = 0.41; p = 0.0003) with an estimated probability of being progression-free at 
6 months and 12 months of 77% and 66% with duvelisib, and 53% and 33% with ofatumumab 
(Figure 2C). Duvelisib maintained a favorable odds ratio relative to ofatumumab for all 
subgroups analyzed, including refractory/early relapse (HR = 0.51), baseline Grade 4 cytopenia 
(HR = 0.14), and prior anticancer therapy within the past 12 months (HR = 0.40). 
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The ORR per IRC response assessment for duvelisib was also significantly higher compared to 
ofatumumab (73.8% versus 45.3%; p < 0.0001) (Figure 3). In the duvelisib arm, nearly all 
responses were PR (72.5%) with the exception of 2 patients; 1 patient achieving a CR (0.6%), 
and 1 patient achieving a PRwL (0.6%). Responses on the ofatumumab arm were also 
predominantly PRs (44.7%) with a CR (0.6%) in 1 patient (Table S2). Duvelisib treatment was 
particularly effective in targeting the lymph node disease compartment, with a lymph node 
response by IRC assessment of 85.0% (95% CI: 79.5, 90.5) compared to 15.7% (95% CI: 10.1, 
21.4) in the ofatumumab arm (p < 0.0001; Figure 3). Median OS was not reached on either 
treatment arm with a 12-month probability of survival of 86% (HR = 0.99; CI: 0.65 , 1.50) for 
both treatments (Figure S2). 
Safety 
AEs were assessed during the treatment periods of each arm. Median treatment exposure was 
approximately twice as long among duvelisib-treated patients (median duration 50 weeks) 
compared to ofatumumab-treated patients (median duration 23 weeks). Per protocol, 
ofatumumab treatment did not exceed the 12 doses (approximately 6 months) specified in the 
ofatumumab prescribing information. As of the data cut-off, 49% of duvelisib-treated patients 
had received more than a year of treatment, with 31% and 12% having received 1.5 years and 2 
years of treatment, respectively. AEs that occurred in ≥ 10% patients during these respective AE 
reporting periods (ie, not exposure matched) are presented in Table 3. Nearly all patients in both 
arms experienced an AE. The most common hematologic AEs with duvelisib and ofatumumab 
were neutropenia (33% and 21%), anemia (23% and 10%) and thrombocytopenia (15% and 6%), 
respectively. The nonhematologic AEs most commonly reported with duvelisib were diarrhea 
(51%), pyrexia (29%), nausea (23%), and cough (21%). Colitis, as a distinct event from diarrhea, 
was reported in 13% with 8% of patients having diarrhea directly preceding and/or overlapping 
with the colitis event. Median time to first event of diarrhea or colitis was approximately 
4 months and 7 months, respectively. With ofatumumab, infusion-related reaction (19%), cough 
(14%), and diarrhea, rash, and fatigue (12% each) were the most common nonhematologic AEs.  
AEs ≥ Grade 3 occurred in 87% of duvelisib arm patients and 48% of ofatumumab arm patients. 
In the duvelisib arm, the most common severe events were neutropenia (30%), diarrhea (15%), 
pneumonia (14%) and anemia (13%). On the ofatumumab arm, only neutropenia (17%) occurred 
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in ≥ 10% of patients. As previously observed in the Phase 1 study,22,24 severe immune-related 
toxicities (≥ Grade 3) were noted in duvelisib-treated patients. In this Phase 3 study, the 
occurrence of severe immune-related toxicities included colitis (12%) and pneumonitis, alanine 
transaminase (ALT) or aspartate transaminase (AST) increase (3% each). While these events 
were primarily managed with dose interruptions, 60% of patients with pneumonitis or colitis 
received steroid therapy with resolution reported in nearly all patients at the time of data cut-off. 
None of these events were fatal.  
Infectious AEs were more frequently reported in the duvelisib arm (69% vs. 43%) with 
pneumonia (18%) and upper respiratory tract infection (URTI, 16%) representing the most 
common events. Pneumocystis jirovecii pneumonia occurred in 3 duvelisib-treated patients and 
1 ofatumumab-treated patient, 3 of whom were not receiving prophylaxis at the time of their 
infections despite being required per protocol and 1 duvelisib-treated patient who discontinued 
prophylaxis due to intolerance. Of the duvelisib-treated patients who discontinued treatment due 
to AEs, colitis and diarrhea were the only AEs occurring in ≥ 5% of patients (both 5%). 
Treatment discontinuations from the other immune-related toxicities of pneumonitis (2%), and 
elevated AST levels (1%) were infrequent. 
Serious AEs (SAEs) are summarized in Table S3. Pneumonia was the most frequently reported 
SAE in both treatment arms (duvelisib 15%; ofatumumab 3%). There were 19 fatal AEs on the 
duvelisib arm (Table S4), 4 of which were assessed by Investigators as related to study drug; 
staphylococcal pneumonia (n = 2), and sepsis and general health deterioration (n = 1 each). On 
the ofatumumab arm, 7 patients had fatal AEs although none were attributed to ofatumumab 
treatment.  
Pharmacodynamic Measurements 
Twenty-four chemokines and cytokines were measured in patient serum samples, and the median 
percent change from baseline to Cycle 2 Day 1 was determined to assess treatment-related 
effects associated with the targeting of leukemia cells and the tumor microenvironment,29,30 as 
described in the Supplemental Methods section. Sixteen chemokines were significantly reduced 
from baseline in duvelisib-treated patients (p <0.05; Figure 4). Ofatumumab-treated patients had 
levels that were not statistically decreased from baseline, whereas the duvelisib-treated patients 
had decreased levels that were highly significant: CCL1 (p < 0.0001), CCL17 (p < 0.0001), 
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CXCL10 (p < 0.0002), CXCL11 (p < 0.0009), CXCL9 (p < 0.0001), and IL10 (p < 0.0001). In 
total, 10 chemokines showed greater than 50% median decreases in duvelisib-treated patients. 
 
Discussion  
In this pivotal Phase 3 DUO study, duvelisib monotherapy resulted in statistically significant 
improvement in PFS and ORR compared to ofatumumab in patients with RR CLL/SLL, 
including those with del(17p)/TP53 mutations. This improvement was consistently observed 
across all sensitivity and subgroup analyses for both efficacy endpoints. In the duvelisib arm, the 
median PFS as determined using Investigator response assessments was notably longer than 
IRC-assessed PFS (17.6 months vs. 13.3 months). This difference likely reflects inherent 
differences in methodologies used to derive responses and determine progression between the 
two evaluator groups. With the IRC PFS largely based upon radiologic data, the Investigator-
derived PFS, incorporating both radiological and real-time clinical assessments, as would be 
applied in the standard oncology care setting, likely represents a more clinically relevant PFS. 
Clinically meaningful reductions in target lymph nodes were observed in most patients treated 
with duvelisib (85%), representing a statistically significant treatment effect over ofatumumab 
(16%) (p < 0.0001). Median OS was similar between the 2 treatment arms, which may be 
explained by the availability of multiple CLL therapies to rescue patients on either arm following 
disease progression, including administration of duvelisib in a separate, optional extension study 
to 89 patients who had confirmed progressive disease on ofatumumab in the DUO study.  
Based on the study design, the treatment period for duvelisib was longer than ofatumumab 
(median exposure 50 weeks versus 23 weeks), which resulted in a longer AE reporting period for 
duvelisib compared to ofatumumab. Of the patients treated with duvelisib, 49%, 31%, and 12% 
received more than a year, 18 months, and 2 years of treatment, respectively. The duvelisib AE 
profile observed in this trial was consistent with the drug safety profile to date,22,24 with the 
majority of AEs presenting as Grade 1 or 2 events. Many of the more common AEs, such as 
cytopenias and constitutional symptoms, are also well-recognized complications of CLL/SLL. 
Similar to other B-cell receptor pathway inhibitors, infections (particularly pneumonias and 
URTIs)31,32 were frequently observed on duvelisib, representing the most common severe and 
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serious AEs; 3 patients died due to treatment-related infections. Although a well-recognized 
major cause of morbidity and mortality in CLL given the humoral immunodepression inherent to 
the disease33,34 and therapy-induced immunosuppression, infections remain an important risk 
with duvelisib treatment. The protocol requirement for Pneumocystis jirovecii pneumonia 
prophylaxis may have mitigated against the risks of these opportunistic infections, which have 
been reported with other B cell receptor inhibitors.35-39 Of interest, the 3 duvelisib-treated 
patients who experienced Pneumocystis jirovecii infections during the study were not receiving 
prophylaxis due to protocol deviations or medication intolerance. 
Several prespecified AEs of interest relating to possible immunomodulatory effects of PI3K-δ/γ 
inhibition40-45 were closely monitored in this study. Incidences of neutropenia, diarrhea, colitis, 
transaminase elevations, pneumonitis, and rash with duvelisib therapy were moderate and 
manageable with early intervention and dose modification as required per protocol. Of these, 
colitis was the most commonly observed severe (≥ Grade 3) event, reported in 12% of duvelisib 
treated patients, while severe cases of pneumonitis, transaminase elevations, and toxic skin 
eruption/rash were reported in < 3%. None of these events were fatal. These potential 
immune-mediated toxicities, identified in clinical studies with the PI3K-δ specific inhibitor 
idelalisib, infrequently led to discontinuations of duvelisib therapy.  
Malignant B cell proliferation and survival in CLL/SLL is promoted by PI3K.10-12 The PI3K-δ/γ 
isoforms are also expressed in cells comprising the tumor microenvironment where they provide 
supportive signaling.13-16 As a dual PI3K-δ/γ inhibitor, duvelisib has the potential to target cell 
autonomous mitogenic and survival signaling as well as the supportive tumor microenvironment 
that further enables CLL proliferation.30,46 An analysis of patient blood protein profiles showed 
significant reductions in the levels of serum chemokines and cytokines associated with malignant 
B cells, consistent with decreases in CLL viability and proliferation, as previously reported.24 
Considering the dual inhibitor action of duvelisib, the pattern of chemokine change may reflect 
the inhibition of both PI3K-δ and PI3K-γ signaling within the tumor microenvironment. 
This report of the DUO study data represents the second Phase 3 randomized trial to investigate 
the safety and efficacy of an oral PI3K inhibitor in relapsed CLL patients. In a prior study, 
idelalisib, an oral inhibitor of the PI3K-δ isoform, in combination with rituximab showed 
improved PFS compared with rituximab monotherapy (not reached versus 5.5 months) and 
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response rate (81% versus 13%) in patients with relapsed CLL who have clinically significant 
coexisting medical conditions.47 The incidence of the more common AEs in the idelalisib + 
rituximab arm, such as cytopenias, constitutional symptoms, and diarrhea, occurred at similar 
rates in the duvelisib arm of the DUO trial. However, at the time of the idelalisib trial analysis, 
patients in the idelalisib + rituximab arm had only received study drug for a median of 3.8 
months compared with the much longer exposure of duvelisib of nearly a year in the DUO trial. 
This large difference in drug exposure and observation periods makes it difficult to compare 
incidences across trials. Additionally, the timing of some immune-mediated toxicities, such as 
colitis and pneumonitis, which tend to emerge with longer drug exposure, may be more 
accurately represented in this study with a longer duration of assessment. Interestingly, however, 
the incidence of high grade transaminitis AEs with duvelisib was low in this study. The AE 
profile with duvelisib monotherapy remains consistent across studies22,23 and manageable with 
appropriate intervention via dose modifications, routine medical care, and prophylactic 
measures. Additional characterization of key safety events associated with the use of idelalisib40 
and PI3K inhibitors as a whole41 has greatly informed the guidance for maximizing safe 
administration of drugs in this class. 
The anti-CD20 monoclonal antibody ofatumumab is approved as monotherapy for the treatment 
of relapsed CLL and represented an accepted and appropriate standard of care agent for 
comparing to duvelisib monotherapy at the time of study initiation. However, the use of single-
agent ofatumumab for the treatment of relapsed CLL has diminished in recent years, being 
supplanted by newer agents that target the B-cell receptor pathway. In addition to idelalisib in 
combination with rituximab, ibrutinib, an oral BTK inhibitor, received full approval in 2014 
based on a Phase 3 randomized study demonstrating significantly improved PFS compared to 
ofatumumab (median PFS not reached versus 8.1 months [HR = 0.22]).7 Treatment indications 
have since expanded to include ibrutinib use as a frontline CLL therapy. Despite advantages of 
being an effective and well-tolerated therapy, it is not curative, and treatment discontinuations 
due to disease progression and drug intolerance have been described in published reports.48-50 
Given the unfortunate reality that many patients have or acquire resistance or intolerance to 
currently-available, targeted therapies, or have comorbidities that may preclude their safe use, 
there remains a critical medical need for additional, novel, targeted therapies for patients with 
RR CLL/SLL, especially those with del(17p)/TP53 mutations. These combined safety and 
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efficacy results suggest that duvelisib monotherapy may offer an effective treatment for 
CLL/SLL patients in need of additional therapeutic options.  
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Table 1. Patient Demographics and Baseline Characteristics 
Abbreviations: 17p deletion = deletion of the 17p13 chromosomal region; CLL = chronic lymphocytic leukemia; 
ECOG = Eastern Cooperative Oncology Group; IGHV = immunoglobin heavy chain variable; PS = performance 
status; SLL = small lymphatic lymphoma. 
a 
 As assessed by study Investigators during screening. 
b  Thrombocytopenia and/or neutropenia. 
c Progression < 12 months after fludarabine/pentostatin. 
Characteristic  Duvelisib 
(n = 160) 
Ofatumumab 
(n = 159) 
Median age (range), years   69 (39-90)   69 (39-89) 
Male, %    60   60 
ECOG PS 2, %   7   10 
CLL/SLL, %   97 / 5   99 / 2 
Median time from initial diagnosis, years   7.5   6.7 
Rai stage ≥ III / Binet Stage C, %   56 / 41   56 / 34 
Bulky disease (≥ 5 cm target lesion), %    46   45 
Enlarged livera, %   18   18 
Enlarged spleena, %   38   32 
Baseline lymphocytes (x 109/L), median   38   35 
Grade 4 Cytopeniab, %   11   11 
Refractory/Early relapse to purine therapyc   31   30 
Molecular features (per central laboratory), % 
     17p deletion   21   28 
     TP53 mutation   20   18 
     17p deletion and/or TP53 mutation    31   33 
     Unmutated IGHV   69   73 
     CD38 Positive   43   44 
     ZAP70 Positive (> 19%)    54   52 
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Table 2. Patient Disposition 
 
Abbreviations: AE = adverse event. 
a
 Completed treatment for ofatumumab = 7 cycles and for duvelisib = 18 cycles (duvelisib-treated patients permitted 
to receive duvelisib ≥ 18 cycles).
Characteristic  Duvelisib Ofatumumab 
Randomized, n  160  159 
Treated, n  158  155 
Median exposure (weeks)  50  23 
Discontinued Treatment, n (%)  124 (79)  155 (100) 
     AE  55 (35)  6 (4) 
     Disease progression  35 (22)  31 (20) 
     Subject withdrawal   13 (8)  7 (5) 
     Death  12 (8)  3 (2) 
     Investigator decision  3 (2)  4 (3) 
     Completed treatment per protocol  1 (1)a  103 (67)a 
     Other  5 (3)  1 (1) 
On Treatment, n (%)  34 (22)  0 
Crossed over to Study IPI-145-12 to receive 
opposite treatment, n (%) 8 (5) 89 (57) 
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Table 3. Adverse Events in ≥ 10% of Duvelisib-treated Patients 
Abbreviations: AE = adverse event; URTI = upper respiratory tract infection. 
 
Adverse Event 
All Grades Grade 3 and above 
Duvelisib Ofatumumab Duvelisib Ofatumumab 
n (%) n (%) n (%) n (%) 
Any AE 156 (99) 144 (93) 138 (87) 75 (48) 
Hematologic AEs 
   Neutropenia 52 (33) 32 (21) 48 (30) 27 (17) 
   Anemia 36 (23) 16 (10) 20 (13) 8 (5) 
   Thrombocytopenia 23 (15) 9 (6) 12 (8) 3 (2) 
Nonhematologic AEs 
   Diarrhea 80 (51) 19 (12) 23 (15) 2 (1) 
   Pyrexia 45 (29) 16 (10) 4 (3) 1 (1) 
   Nausea 37 (23) 17 (11) 0 0 
   Cough 33 (21) 22 (14) 2 (1) 0 
   Pneumonia 29 (18) 9 (6) 22 (14) 2 (1) 
   Constipation 26 (17) 13 (8) 1 (1) 0 
   URTI 25 (16) 12 (8) 0 0 
   Vomiting 23 (15) 10 (7) 0 0 
   Bronchitis 21 (13) 13 (8) 5 (3) 1 (1) 
   Colitis 21 (13) 2 (1) 19 (12) 1 (1) 
   Fatigue 20 (13) 19 (12) 2 (1) 2 (1) 
   Decreased appetite 20 (13) 5 (3) 0 1 (1) 
   Weight decreased 18 (11) 3 (2) 0 0 
   Asthenia 18 (11) 17 (11) 3 (2) 4 (3) 
   Abdominal pain 16 (10) 3 (2) 3 (2) 0 
   Dyspnea 16 (10) 9 (6) 4 (3) 0 
   Rash 16 (10) 18 (12) 3 (2) 1 (1) 
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Figure 1.  Progression-free survival in the study population. Kaplan-Meier curves of PFS 
assessments in CLL/SLL patients treated with monotherapy duvelisib or ofatumumab. PFS was 
significantly longer for duvelisib-treated patients compared to ofatumumab-treated patients by 
assessments of (A) blinded IRC (13.3 months vs. 9.9 months, HR = 0.52, p < 0.0001) and (B) 
Investigators (17.6 months vs. 9.7 months, HR = 0.40; p < 0.0001).  Abbreviations: BID = twice 
daily; CI= confidence interval; DUV = duvelisib; PFS = progression-free survival; 
OFA = ofatumumab. 
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Figure 2. Progression-free survival in selected study subgroups. (A). Forest plot and hazard 
ratios for PFS per IRC assessment on duvelisib or ofatumumab monotherapy for predefined 
subgroups within the total study population. Kaplan-Meier curves of progression-free survival 
per IRC assessment (B) and Investigator assessment (C) in the subgroup of patients with 
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del(17p)/TP53 mutation. In this high-risk subgroup, median PFS was 12.7 months and 
9.0 months (HR = 0.40, p = 0.0002) by IRC assessment and 13.8 months and 9.5 months 
(HR = 0.41, p = 0.0003) by Investigator assessment for duvelisib and ofatumumab, respectively. 
Abbreviations: BID = twice daily; CI = confidence interval; DUV = duvelisib; 
OFA = ofatumumab; Refractory/Early Relapse = Refractory/Early Relapse to Purine Analog-
Based Therapy; Prior Anticancer Therapy = Most Recent Prior Anticancer Therapy from 
Randomization; HR = Hazard Ratio; LCL = Lower Confidence Limit; UCL = Upper Confidence 
Limit. 
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Figure 3. ORR per IRC assessment and lymph node response rate for the total CLL/SLL 
study population for duvelisib versus ofatumumab monotherapy. Lymph node response was 
defined as ≥ 50% decrease in the sum of the products of target lymph nodes. Both the ORR 
(p < 0.0001) and the lymph node response rate (p < 0.0001) were significantly higher in 
duvelisib-treated patients. Abbreviations: CLL = chronic lymphocytic leukemia; IRC = 
independent review committee; ORR = overall response rate; SLL = small lymphatic lymphoma. 
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Figure 4. Cytokine and chemokine changes in CLL/SLL patients treated with duvelisib or 
ofatumumab. The median percent change from Baseline to Cycle 2 Day 1 is depicted. The 10 
cytokines and chemokines that showed greater than 50% median reductions in duvelisib patients 
from baseline are denoted with an asterisk. Abbreviations: BID = twice daily; CLL = chronic 
lymphocytic leukemia; SLL = small lymphatic lymphoma. 
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